CGRP peptide antagonists and conjugates
AssigneeAmgen Inc.
InventorsColin V. Gegg, Jr., Eileen J. Johnson, Leslie P. Miranda, Kenneth W. Walker, Jerry Ryan Holder, Marie E. Wright, Derin C. D'Amico
Life of this patent
Estimating the term…
Abstract
Disclosed is a composition of matter that involves a CGRP peptide antagonist. A pharmaceutical composition is disclosed that comprises the composition of matter and a pharmaceutically acceptable carrier, which can be configured for administration to a patient. Also disclosed is a method of producing the composition of matter. Methods of treating, preventing or mitigating migraine, are also disclosed.
Claims11
A composition of matter, comprising a CGRP peptide antagonist comprising an amino acid sequence of the formula:
- (SEQ ID NO:
- 1127)
- Xaa1Xaa2Xaa3Xaa4Xaa5Xaa6Xaa7V8Xaa9Xaa10Xaa11L12A13
- G14L15L16S17Xaa18S19G20G21V22Xaa23Xaa24Xaa25Xaa26
- F27V28P29Xaa30Xaa31V32G33Xaa34Xaa35A36Xaa37
- wherein:
- Xaa1, Xaa2, Xaa3 Xaa4, Xaa5, Xaa6, and Xaa7, are each independently absent or a hydrophobic amino acid residue selected from Trp, 1-Nal, 2-Nal, Phe, Tyr, Bip, 4-carboxy-phenylalanine, and 4-Amino-Phe;
- Xaa9 is a Thr, Ser, Ala, Gly, Val, Leu, or Ile residue;
- Xaa10 is a His, Nα-Methyl-His, Lys, Homolysine, Ornithine, or 4-Amino-Phe residue;
- Xaa11 is an Nα-Methyl-Arg, homoarginine, Cit, Nα-Methyl-Cit, Homocitrulline, His, Guf, Lys, Homolysine, Ornithine, or 4-Amino-Phe residue;
- Xaa18 is an Nα-Methyl-Arg, homoarginine, Cit, Nα-Methyl-Cit, Homocitrulline, His, Guf, Lys, Homolysine, Ornithine, or 4-Amino-Phe residue;
- Xaa23 is a Val, Arg, D-Arg, homoarginine, Lys, D-Lys, homolysine, Orn, Dab, Dpr, homocysteine, or 4-Amino-Phe residue;
- Xaa24 is an Arg, D-Arg, Homoarginine, Lys, D-Lys, Homolysine, Orn, Dab, Dpr, Homocysteine, or 4-Amino-Phe residue;
- Xaa25 is an Arg, D-Arg, Homoarginine, Lys, D-Lys, Homolysine, Orn, Dab, Dpr, Homocysteine, or 4-Amino-Phe residue;
- Xaa26 is an Asn, Arg, D-Arg, Homoarginine, Lys, D-Lys, Homolysine, Orn, Dab, Dpr, Homocysteine, or 4-Amino-Phe residue;
- Xaa30 is a Thr, Nα-Methyl-Thr, Ser, or Nα-Methyl-Ser residue;
- Xaa31 is an Asn, Lys, Homolysine, Ornithine, 4-carboxy-phenylalanine, 4-Amino-Phe, beta-glutamic acid, beta-Homoglutamic acid, homoglutamic acid, or Asp residue;
- Xaa34 is an Oic, Pro, Hyp, Tic, D-Tic, D-Pro, Thz, Aib, Sar, or Pip residue;
- Xaa35 is a Phe, D-Phe, Tyr, 1-Nal, 2-Nal, Trp, or Bip residue;
- and
- Xaa37 is a Phe, Tyr, 1-Nal, 2-Nal, Trp, Bip, 4-carboxy-phenylalanine, or 4-Amino-Phe residue.
A composition of matter, comprising a CGRP peptide antagonist comprising the amino acid sequence of SEQ ID NO:658.
A composition of matter, comprising a CGRP peptide antagonist having the amino acid primary sequence of any of those set forth in SEQ ID NOS:
- 25, 31, 658, 674, 739, 920, or 926.
Dependencies are inferred from the claim text.